COMMUNIQUÉS West-GlobeNewswire

-
Assure Announces Further Extension of Exchange Offer Relating to its Convertible Notes
19/08/2024 -
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
19/08/2024 -
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/08/2024 -
Calibre Scientific Acquires Industrial Glassware, a U.S. Manufacturer and Provider of Laboratory Supplies and Consumables
19/08/2024 -
BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
19/08/2024 -
Kraig Biocraft Laboratories Successfully Completes Third Commercial Spider Silk Production Cycle
19/08/2024 -
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
19/08/2024 -
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
19/08/2024 -
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
19/08/2024 -
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
17/08/2024 -
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders
17/08/2024 -
Cannara Biotech atteint sa part de marché nationale la plus élevée, soit 3,2 %, en juillet 2024 et annonce la tenue d’une webdiffusion pour les investisseurs le 20 août 2024
17/08/2024 -
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
16/08/2024 -
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
16/08/2024 -
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
16/08/2024 -
Alignment Healthcare Updates its Board of Directors
16/08/2024 -
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
16/08/2024 -
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
16/08/2024 -
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
16/08/2024
Pages